相关实验视频
Updated: Sep 9, 2025

08:15
Gastrointestinal Motility Monitor GIMM
Published on: December 1, 2010
31.0K
在功能性便秘的小鼠中,Piezo knockdown减少了5 - 基胺从肠染色素细胞释放,并加剧了肠道功能障碍
Xiangyun Yan1, Peitao Ma1, Wen Wang1
1School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P.R. China.
International journal of molecular medicine
|September 5, 2025
概括
在功能性便秘中,皮埃佐1和皮埃佐2通道对维持肠道健康和血清素分泌至关重要. 它们在肠染色素细胞中的联合作用对正常肠道功能至关重要.
科学领域:
- 胃肠病学
- 分子生物学
- 细胞生理学
背景情况:
- 肠染色素 (EC) 细胞功能障碍和降低的5-三胺 (5-HT) 分泌与功能性便秘 (FC) 有关.
- 关联EC细胞功能与FC病变的确切机制,特别是涉及离子通道,仍然在很大程度上是未知的.
- 已知皮埃佐离子通道可以调节EC细胞中的5-HT释放.
研究的目的:
- 研究Piezo1和Piezo2在功能性便秘的发病过程中的作用和潜在机制.
- 探索Piezo1和Piezo2在调节EC细胞功能和肠道平衡中的合作相互作用.
- 在FC模型中评估Piezo通道功能障碍对5-HT信号传递和胃肠道运动的影响.
主要方法:
- 使用洛佩拉胺诱导的功能性便秘小鼠模型.
- 在小鼠体内的Piezo1和Piezo2中使用腺相关病毒.
- 在QGP-1细胞系 (EC类细胞) 中进行了用lentiviral介导的试验.
- 评估了肠道运动,胃肠道通行,胃排空和小肠道推进.
- 测定了5-HT,5-HT3受体,基酶-1 (TPH-1),P物质,血清素转运体,ERK和PKC酸化的水平.
主要成果:
- 在FC小鼠中观察到Piezo1和Piezo2与EC细胞的减少表达和同位化.
- 抑制Piezo1或Piezo2导致肠道运动功能受损,肠道过渡速度减慢,胃排空时间延迟,推进力减弱.
- 在Piezo通道中断后,5-HT,5-HT3受体和TPH-1水平下降.
- 双击加剧了FC症状,导致结肠异常和神经递质/ 递质水平的改变.
- 皮埃佐通道敲除抑制了ERK和PKC酸化,双重敲除对PKC产生了更明显的作用.
- 在实验室中,EC类细胞的双击导致细胞内,5-HT和TPH-1的显著降低.
结论:
- 在功能性便秘中,Piezo1和Piezo2在维持肠道平衡方面发挥着关键的合作作用.
- 这些通道共同调节EC细胞中的离子流入,从而协调5-HT信号.
- 向皮耶索通道为治疗功能性便秘提供了一个潜在的新疗法.
相关概念视频
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
395
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
395
Drugs for Treatment of Constipation-Predominant IBS
322
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
322
Drugs for Treatment of Diarrhea-Predominant IBS
289
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
289
Drugs Affecting GI Tract Motility: Other Laxatives
443
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
443
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
591
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
591
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
303
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
303

